Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Gains from Investment Securities (2022 - 2025)

Corvus Pharmaceuticals has reported Gains from Investment Securities over the past 4 years, most recently at $300000.0 for Q3 2025.

  • Quarterly results put Gains from Investment Securities at $300000.0 for Q3 2025, down 61.29% from a year ago — trailing twelve months through Dec 2025 was $8.1 million (changed N/A YoY), and the annual figure for FY2025 was -$27.1 million, down 1052.08%.
  • Gains from Investment Securities for Q3 2025 was $300000.0 at Corvus Pharmaceuticals, down from $5.6 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for CRVS hit a ceiling of $34.3 million in Q4 2024 and a floor of -$25.1 million in Q1 2025.
  • Median Gains from Investment Securities over the past 4 years was $300000.0 (2025), compared with a mean of $1.3 million.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 10380.0% in 2023 and later skyrocketed 3433.17% in 2024.
  • Corvus Pharmaceuticals' Gains from Investment Securities stood at $10000.0 in 2022, then tumbled by 10380.0% to -$1.0 million in 2023, then skyrocketed by 3433.17% to $34.3 million in 2024, then crashed by 99.12% to $300000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $300000.0 (Q3 2025), $5.6 million (Q2 2025), and -$25.1 million (Q1 2025) per Business Quant data.